STOCK TITAN

Bolt Biotherapeutics Inc - BOLT STOCK NEWS

Welcome to our dedicated news page for Bolt Biotherapeutics (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bolt Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bolt Biotherapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
Bolt Biotherapeutics Inc

Nasdaq:BOLT

BOLT Rankings

BOLT Stock Data

46.52M
20.98M
3.94%
59.57%
4.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Redwood City

About BOLT

bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.